Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Follicular lymphoma, drawn from the whole corpus: 58 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Transformation to DLBCL cannot be predicted or prevented.
Sequencing bispecifics vs CAR-T.
Whether earlier intensive therapy for POD24 patients improves survival.
Late toxicities of decades of therapy (secondary cancers, infections, immunoglobulin loss).
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 32 changes by month →When this page itself was last checked or edited.
Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.
Accelerated approval in follicular lymphoma
R/R follicular lymphoma after ≥2 lines (accelerated)
Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)
R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)